摘要:
In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要:
In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single Glade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要:
In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要:
The invention provides a composition comprising four adenoviral vectors, each comprising a nucleic acid sequence encoding a clade A HIV Env protein, a clade B HIV Env protein, a clade C HIV Env protein, and a clade B HIV Gag-Pol fusion protein, respectively. The invention also provides a method of inducing an immune response against HIV-1 in an animal comprising administering the composition to the animal.
摘要翻译:本发明提供包含四种腺病毒载体的组合物,每种腺病毒载体分别包含编码进化枝A HIV Env蛋白,进化枝B HIV Env蛋白,进化枝C HIV Env蛋白和进化枝B HIV Gag-Pol融合蛋白的核酸序列 。 本发明还提供了一种在动物中诱导针对HIV-1的免疫应答的方法,其包括向所述动物施用所述组合物。
摘要:
The invention provides a composition comprising a pharmaceutically acceptable carrier and six plasmids, each of which encodes an HIV Env, Gag, Pol, or Nef protein. The invention also provides a method of inducing an immune response in an animal using the composition.
摘要:
In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要:
The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
摘要:
The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
摘要:
The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
摘要:
These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.